Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock Price, Quote & AI Analysis

Live BDTX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Black Diamond Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Black Diamond Therapeutics, Inc. Common Stock (BDTX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

BDTX
Black Diamond Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
2.190000
High
2.270000
Low
2.190000
Volume
227,451
VWAP
-
Market Cap
$122,597,925.00
52W Range
$1.20 - $4.94
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
May 11, 2026 Q1
Market
EPS Estimate: $-0.0189
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Black Diamond Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Black Diamond Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Company Details
Market Cap
$127.47M
Shares Outstanding
57,288,752
Weighted Shares Outstanding
57,288,750
CEO
Mark A. Velleca
Address
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
Employees
21
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Black Diamond Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...